Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholan

Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma

Please note that information regarding clinical trials is being Provided for informational purposes only.The Cholangiocarcinoma Foundation does not endorse any specific clinical trial. Please discuss any questions you may have about clinical trials with your healthcare provider.

https://clinicaltrials.gov/ct2/show/NCT03383796

Study Description

Go to
Brief Summary:
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy and the second most common primary hepatic malignancy. The prognosis of CCA is dismal. Surgery is the only potentially curative treatment, but the majority of patients present with advanced stage disease, and recurrence after resection is common. It is classified into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes. Among all, pCCA is the most common subtype.

This is a prospective, randomized, controlled multicenter trial with two treatment arms, three dimension laparoscopic approach versus open approach. The trial hypothesis is that three dimension laparoscopic surgery has advantages in postoperative recoveries and be equivalent in operation time, oncological results and long-term follow-up compared with open counterpart. The duration of the entire trial is two years including prearrangement, follow-up and analyses.

Condition or disease
Intervention/treatment
Cholangiocarcinoma, PerihilarSurgery
Procedure: Three dimensional laparoscopic resection for pCCAProcedure: Open resection for pCCA

 

Study Design

Go to
 

Study Type  :
Interventional  (Clinical Trial)
Estimated Enrollment  :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomized Clinical Trial Comparing Three Dimension Laparoscopic and Open Surgery for Perihiliar Cholangiocarcinoma
Anticipated Study Start Date  :
March 1, 2018
Estimated Primary Completion Date  :
March 1, 2018
Estimated Study Completion Date  :
March 1, 2020
Resource links provided by the National Library of Medicine

 

Genetics Home Reference related topics: Cholangiocarcinoma
Genetic and Rare Diseases Information Center resources: Bile Duct Cancer Klatskin Tumor
U.S. FDA Resources

 

Arms and Interventions

Go to
Arm
Intervention/treatment
Experimental: 3D approachThree dimensional laparoscopic resection for pCCA
Procedure: Three dimensional laparoscopic resection for pCCAThree dimensional laparoscopic resection for pCCA
Experimental: open approachOpen resection for pCCA
Procedure: Open resection for pCCAOpen resection for pCCA

 

Outcome Measures

Go to

Primary Outcome Measures  :Mortality [ Time Frame: 24 months ]Mortality was defined as any death that occurred in the 30 days after surgery or during the hospital stay.

 

Length of Stay [ Time Frame: 24 months ]Length of stay was defined as the postoperative time interval in days.

 

R0 Resection Rate [ Time Frame: 24 months ]Negative margin rate.

 

Bile leakage [ Time Frame: 24 months ]The drain bilirubin was monitored after surgery, any elevation for the bilirubin level or the diagnostic puncture proved bile fluid in abdominal cavity.

 

TNM Staging [ Time Frame: 24 months ]According to AJCC guideline, each patients TNM staging were recorded.

 

Complication rate [ Time Frame: 24 months ]Complication Rate Measure Description Any complication mentioned in the protocol should be carefully record and analyzed, including postoperative hemorrhage, postoperative pancreatic fistula, etc.

 

 

Eligibility Criteria

Go to

 

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

 

Ages Eligible for Study:
18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:

Histologically proven pCCA.
Highly presumed perihlar bile duct malignancy with difficulties to obtain histological evidence.
Preoperative staging work up performed by upper abdomen enhanced CT scan.
The subject understands the nature of this trial and willing to comply.
Ability to provide written informed consent.
Patients treated with curative intent in accordance to international guidelines
Exclusion Criteria:

Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node metastases, involvement of other organs.
Subjects undergoing any part for hepatectomy.
Patients with high operative risk as defined by the American Society of Anesthesiologists (ASA) score >4.
Synchronous malignancy in other organs.
Palliative surgery
Contacts and Locations

Go to

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03383796

Locations

China, Hubei
Tongji Hospital
Not yet recruiting
Wuhan, Hubei, China, 430000
Contact: Hang Zhang, M.D.    +8613407148260    okashiiyo@126.com
Tongji Hospital
Recruiting
Wuhan, Hubei, China
Contact: Min Wang, Dr.    +8602783665314    wangmin0013128@aliyun.com
Sponsors and Collaborators
Tongji Hospital
More Information

Go to

 

Responsible Party:
Renyi Qin, Clinical professor, Tongji Hospital
ClinicalTrials.gov Identifier:
NCT03383796     History of Changes
Other Study ID Numbers:
TJDBPS02

First Posted:
December 25, 2017    Key Record Dates
Last Update Posted:
December 25, 2017
Last Verified:
December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Undecided

Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Keywords provided by Renyi Qin, Tongji Hospital:
Cholangiocarcinoma perihilar
three dimension laparoscopic